预约演示
Xenetic to advance DNase programme with UVA partnership
2024-01-18
引进/卖出免疫疗法临床研究
Under the agreement, the parties will develop Xenetic’s DNase-based platform. Credit: Maksim Shmeljov/Shutterstock.com.
Xenetic Biosciences has entered into research Xenetic and material transfer agreements with the University of Virginia (UVA) in the US to advance its systemic deoxyribonuclease (DNase) programme.
Xenetic Biosciencesvelop Xenetic’s DNase-based oncology platform.University of Virginia (UVA)
The platform acts on neutXeneticextracellular traps (NETs), weblike structures that comprise extracellular chromatin covered with histones and other proteins.
The new initiative addresses NETs associated with inflammatory and autoimmune diseases, as well as cancer progression.
Excessive levels of NETs can create pro-tumorigeniinflammatory and autoimmune diseaseseness of canccancerrapies.
The platform is designed to complement existing cancer treatments including immunotherapies.cancer
The agreements grant Xenetic an option to solelycancerse any new intellectual property resulting from the DNase research programme. This is in addition to advancing the existing intellectual property of Xenetic.
The company is preparing for a first-in-human clinical trial to assess DNase plus immune checkpoint inhibitors or chemotherapy.
Xenetic CEO Jeffrey Eisenberg stated: “We believe the data generated by our researimmune checkpoint inhibitorsimmune checkpoint inhibitorsimmune checkpoint inhibitorstions are key to fully unlocking the potential of our DNase technology and importantly, providing translational insights as we drive a clinical path for our lead solid tumour indications.
Xeneticagreements provide a significant addition to our development capabilities and resources, and we believe it bolsters our opportunity to accelerate development timelines.solid tumour
“Additionally, we are pleased to deepen our work with Dr Tsung, who has provided a valuable perspective to our team and significant insight for our DNase platform.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。